Losartan (DuP-753) is an angiotensin II receptor antagonist.

AT1 receptor:20 nM

Losartan 与血管紧张素II竞争性地结合AT1受体。其抑制血管紧张素II结合50%所需浓度（IC50）为20 nM[1]。Losartan （40μM）影响ISC，但可阻止ANGII对ISC的作用[2]。Losartan 显著降低血管紧张素II介导的子宫内膜癌细胞增殖。Losartan 与抗miR-155联合使用，相比单药治疗具有更显著的抑制增殖效果[3]。

与安慰剂处理的 Fbn1C1039 g/+ 小鼠相比，Losartan （0.6 g/L，p.o.）处理的 Fbn1C1039 g/+ 小鼠显示出远端气室口径的缩小。Losartan 和普萘洛尔的剂量经过滴定，可产生血液动力学效应。对 pSmad2 核染色的分析表明，Losartan 能拮抗 Fbn1C1039 g/+ 小鼠主动脉壁的 TGF-β 信号传导。Losartan 能改善肺部的疾病表现，但这与血液动力学的改善并无必然联系[4]。Losartan （10 mg/kg，动脉内注射）可使血液中的血管紧张素水平增加 4 到 6 倍。Losartan （10 mg/kg，静脉注射）可使血浆肾素水平增加 100 倍，血浆血管紧张素原水平降至对照组的 24%，血浆醛固酮水平保持不变[5]。

An MTT assay is used to measure cell proliferation and viability. For the assay, 5000 cells in 200?μL media per well are seeded in a 96 well plate. After overnight incubation to allow for cell attachment, the medium is removed by suction. MTT at 1?mg/mL concentration in serum-free medium is added and then incubated for 4?h at 37°C. After removal of MTT solution, 100?μL of DMSO is added to dissolve formazan crystals. Absorbance at 570?nm and at 600?nm as a reference is then measured using a microplate reader. The difference in absorbance is thus relative to the extent of cell survival.